• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe: Te

  2026-06-11

  DiI (DiIC18(3)) offers selective, high-contrast plasma membrane labeling for researchers needing to visualize membrane dynamics, perform neuronal tracing, or quantify cell migration. It is not suitable for aqueous-only protocols or for targeting non-membrane organelles, and requires careful attention to solvent selection and membrane integrity for optimal performance.

• Wnt-C59: Selective PORCN Inhibitor for Wnt Pathway Research

  2026-06-10

  Wnt-C59 is a highly potent, selective PORCN inhibitor that abolishes Wnt secretion, directly impacting Wnt/β-catenin signaling and cancer cell viability. APExBIO's Wnt-C59 demonstrates nanomolar efficacy in vitro and in vivo, offering a robust tool for dissecting Wnt-driven biological processes and therapeutic strategies.

• Targeting SCUBE3: A New Strategy for Suppressing Tumor Progr

  2026-06-10

  The referenced study identifies SCUBE3 as a crucial secreted protein promoting tumor growth, therapy resistance, and immunosuppression across cancer types. By engineering a neutralizing antibody against SCUBE3, the research demonstrates significant inhibition of oncogenic signaling and restoration of antitumor immunity, highlighting a novel, potentially pan-cancer therapeutic avenue.

• 2-(4,5,6,7-tetrabromo...) Small Molecule Inhibitor in LLPS R

  2026-06-09

  The CK2 and ERK8 inhibitor, a tetrabromo benzimidazole derivative, empowers advanced kinase and phase separation studies via precise modulation of phosphorylation pathways. Discover robust workflows, troubleshooting strategies, and translational insights bridging kinase signaling with emergent LLPS research.

• APOC1 as a Target in Papillary Thyroid Carcinoma: Cyclopamin

  2026-06-09

  This study identifies apolipoprotein C1 (APOC1) as a molecular driver of papillary thyroid carcinoma (PTC) progression and immune evasion. It further demonstrates that the Hedgehog signaling inhibitor cyclopamine can suppress PTC growth, especially when APOC1 is depleted, suggesting a new therapeutic avenue for aggressive thyroid cancers.

• Dexamethasone: Glucocorticoid Anti-Inflammatory in Workflow

  2026-06-08

  Dexamethasone (DHAP) from APExBIO empowers researchers to precisely inhibit NF-κB signaling, modulate immune cell differentiation, and drive reproducible neuroinflammation and stem cell assays. Discover protocol refinements, troubleshooting tactics, and evidence-based benchmarks that set this glucocorticoid anti-inflammatory apart in translational research.

• SAR131675 in Tumor Microenvironment Research: Beyond Lymphan

  2026-06-08

  Explore how SAR131675, a potent VEGFR-3 inhibitor, uniquely illuminates the interplay between lymphangiogenesis, angiogenesis, and metabolic side effects in the tumor microenvironment. This article provides advanced insights for researchers optimizing anti-lymphangiogenic strategies.

• Ferrostatin-1 (Fer-1): Guiding Translational Ferroptosis Res

  2026-06-07

  This article provides an advanced thought-leadership perspective on the role of Ferrostatin-1 (Fer-1) in translational research, integrating mechanistic insights, experimental best practices, and strategic guidance. It draws on recent evidence from both primary literature and cross-domain studies to position Fer-1 as a critical tool for interrogating iron-dependent cell death in disease models, outlining its impact on research design, clinical relevance, and future innovation.

• Saquinavir in Translational HIV Research: Advanced Permeabil

  2026-06-06

  Explore how Saquinavir, a potent HIV protease inhibitor, enables advanced antiretroviral drug research and benefits from cutting-edge biomimetic permeability modeling. This article reveals practical experimental guidance and unique translational perspectives beyond standard reviews.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody: Technical Guide

  2026-06-05

  The Cy3 Goat Anti-Mouse IgG (H+L) Antibody provides sensitive and specific detection of mouse IgG in immunoassays requiring fluorescence readout. It is suitable for immunofluorescence, flow cytometry, and western blotting, but is not validated for diagnostic or clinical applications. Researchers benefit from robust signal amplification, while adhering to recommended handling and storage is critical for reproducible results.

• Brefeldin A: Precision Tool for ER Stress and Cancer Researc

  2026-06-05

  Brefeldin A (BFA) is the gold-standard ER stress inducer and vesicle transport inhibitor, enabling researchers to dissect apoptosis mechanisms and protein trafficking in cancer models with unmatched specificity. This article details advanced workflows, protocol optimizations, and troubleshooting strategies to maximize BFA’s research utility.

• 3-Deazaneplanocin (DZNep): Protocols & Innovations in Epigen

  2026-06-04

  3-Deazaneplanocin (DZNep) is revolutionizing epigenetic research, offering reproducible, potent inhibition of key regulators in cancer and metabolic disease models. This guide provides actionable protocols, troubleshooting strategies, and insights from recent breakthroughs, ensuring robust outcomes for advanced oncology and stem cell targeting workflows.

• Ibrexafungerp and Caspofungin: Targeting Resistant Candida a

  2026-06-04

  Wiederhold et al. provide compelling preclinical evidence that both ibrexafungerp, a novel triterpenoid, and caspofungin, a lipopeptide antifungal, effectively reduce fungal burden and improve survival in murine models of invasive candidiasis caused by fluconazole-resistant Candida auris. Their findings highlight the critical role of β-(1,3)-D-glucan biosynthesis inhibition in advancing antifungal strategies against multidrug-resistant pathogens.

• Mitochondrial Apoptosis Uncoupled from Muscle Atrophy in Ova

  2026-06-03

  This study investigates whether mitochondrial ROS-induced apoptosis or necroptosis drive skeletal muscle wasting in metastatic ovarian cancer. Using a mouse model and the mitochondrial-targeted antioxidant SkQ1, the authors show that suppressing mitochondrial caspase activity does not prevent muscle atrophy, challenging widely held assumptions about cell death pathways in cancer cachexia.

• Bafilomycin C1: Vacuolar H+-ATPases Inhibitor in Autophagy W

  2026-06-03

  Bafilomycin C1 stands out as a gold-standard vacuolar H+-ATPases inhibitor, empowering high-content autophagy and cardiotoxicity assays in stem cell-derived models. Its precision enables robust phenotypic screening and deep learning integration, addressing critical challenges in early-stage drug discovery.

450 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page